Ongoing R&D investment in therapeutic apps and medical platforms
First written in FY2022. 9 of 14 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026R&D expenses declined but remained ongoingAnnual report
「The total R&D expenses incurred by the company during the fiscal year were ¥247.459 million, accounting for approximately 29.9% of total business expenses. The company intends to continue its R&D activities, and expects to incur a corresponding level of R&D expenses going forward.」
R&D expenses declined from ¥273.634 million in the previous fiscal year to ¥247.459 million, but accounted for approximately 29.9% of business expenses, and the company indicated that it intends to continue these activities. - 2026-08-07SoftenedEarnings
「We will continue to make upfront investments in research and development and human resources for future growth and advance the business.」
The policy of continuing research and development investment was stated, while research and development expenses decreased from ¥273,634 thousand to ¥247,459 thousand. - FY2026-H1RestatedAnnual report
「The total amount of the Company's research and development expenses during the interim accounting period was ¥112.918 million. There were no significant changes in the status of the Company's research and development activities during the interim accounting period.」
The Company stated that there had been no significant changes in its research and development activities and recorded ¥112.918 million in research and development expenses during the interim accounting period. - FY2025AdvancedAnnual report
「Total R&D expenses incurred by the company during the fiscal year were ¥273.634 million, accounting for a substantial 35.9% of total business expenses. The company intends to continue its R&D activities and expects to incur a corresponding level of R&D expenses going forward.」
R&D expenses increased from ¥243.352 million in the previous fiscal year to ¥273.634 million, accounting for 35.9% of total business expenses. The company also reaffirmed its policy of continuing to invest in therapeutic applications and platform development. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim accounting period were ¥135.661 million. There were no material changes in the company's R&D activities during the interim accounting period.」
The company stated that there were no material changes in its R&D activities and recorded R&D expenses of ¥135.661 million for the interim accounting period. - FY2024AdvancedAnnual report
「Total R&D expenses incurred by the company during the fiscal year were ¥243.352 million, accounting for a substantial 34.4% of total business expenses. The company intends to continue its R&D activities and expects to incur a corresponding level of R&D expenses going forward.」
R&D expenses increased from ¥176.311 million in the previous fiscal year to ¥243.352 million, and the company disclosed that it would continue investing in therapeutic applications and platform development. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative nine-month period were ¥178.803 million. There were no material changes in the company's R&D activities during the cumulative nine-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥178.803 million for the cumulative third quarter. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative six-month period were ¥119.180 million. There were no material changes in the company's R&D activities during the cumulative six-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥119.180 million for the cumulative second quarter. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative three-month period were ¥58.311 million. There were no material changes in the company's R&D activities during the cumulative three-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥58.311 million for the cumulative first quarter. - FY2023RestatedAnnual report
「Total R&D expenses incurred by the company during the fiscal year were ¥176.311 million, accounting for a substantial 30.5% of total business expenses. The company intends to continue its R&D activities and expects to incur a corresponding level of R&D expenses going forward.」
The company disclosed its policy of continuing R&D investment in therapeutic applications and platform systems, together with actual expenses of ¥176.311 million. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative nine-month period were ¥114.692 million. There were no material changes in the company's R&D activities during the cumulative nine-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥114.692 million for the cumulative third quarter. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative six-month period were ¥62.556 million. There were no material changes in the company's R&D activities during the cumulative six-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥62.556 million for the cumulative second quarter. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative three-month period were ¥25.637 million. There were no material changes in the company's R&D activities during the cumulative three-month period.」
The company stated that there were no material changes in its R&D activities and reported total R&D expenses of ¥25.637 million for the quarter. - FY2022First statedAnnual report
「Total R&D expenses for the fiscal year were ¥226.369 million, accounting for a substantial 41.5% of total business expenses.」
The company has indicated, together with the relevant figures, that it is concentrating resources on therapeutic applications and healthcare industry platform systems and will continue its R&D going forward.